Nonhematopoietic Variants of Erythropoietin in Ischemic Stroke: Need for Step-Wise Proof-of-Concept Studies

Neuroprotective, but not hematopoietic, variants of erythropoietin (EPO), such as Neuro-EPO, are promising candidates for treatment in the acute and subacute stroke phase. Characterized by its low sialic acid content and therefore exhibiting a very short plasma half-life, Neuro-EPO can probably not...

Descripción completa

Detalles Bibliográficos
Autor principal: Hermann, Dirk M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: TheScientificWorldJOURNAL 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763796/
https://www.ncbi.nlm.nih.gov/pubmed/21103797
http://dx.doi.org/10.1100/tsw.2010.226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763796/
https://www.ncbi.nlm.nih.gov/pubmed/21103797
http://dx.doi.org/10.1100/tsw.2010.226

Ejemplares similares